NA
NRXP icon

NewEdge Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

NewEdge Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-83
Closed -$183 – 4067
2024
Q4 		$183 Hold
83
– – ﹤0.01% 3749
2024
Q3 		$140 Sell
83
-500
-86% -$1.01K ﹤0.01% 3703
2024
Q2 		$1.42K Hold
583
– – ﹤0.01% 3392
2024
Q1 		$2.75K Sell
583
-130
-18% -$599 ﹤0.01% 3309
2023
Q4 		$3.28K Hold
713
– – ﹤0.01% 3238
2023
Q3 		$1.85K Buy
713
+500
+235% +$1.66K ﹤0.01% 3071
2023
Q2 		$1.03K Hold
213
– – ﹤0.01% 3241
2023
Q1 		$1.4K Buy
213
+130
+157% +$1.32K ﹤0.01% 3103
2022
Q4 		$1 Buy
+83
New +$836 ﹤0.01% 4025

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

NewEdge Advisors's NRXP Position: Q1 2025 in Review

NewEdge Advisors sold out of NRX Pharmaceuticals (NRXP) in Q1 2025, closing a stake of 83 shares — an estimated $183 sold.

NewEdge Advisors first reported a position in NRXP in Q4 2022 and held it in 9 quarters. The position peaked at $3.28K in Q4 2023. 22 funds tracked by Wall St. Rank hold NRXP as of Q1 2025.

  • NewEdge Advisors reported no remaining NRX Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • NewEdge Advisors sold 83 NRX Pharmaceuticals shares in Q1 2025, an estimated $183.
  • NewEdge Advisors first reported a position in NRX Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • NewEdge Advisors's NRX Pharmaceuticals position peaked at $3.28K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2025.

Based on NewEdge Advisors's 13F filing for Q1 2025, filed 15 May 2025.